Article Text

PDF
Zygomatico-orbital intra-arterial melphalan infusion for intraocular retinoblastoma
  1. Daniel Cooke,
  2. Hamed Farid,
  3. Warren Kim,
  4. Christopher Dowd,
  5. Randall Higashida,
  6. Van Halbach
  1. Department of Radiology and Biomedical Imaging, University California San Francisco, San Francisco, California, USA
  1. Correspondence to Dr Daniel Cooke, Department of Radiology and Biomedical Imaging, University California San Francisco, 505 Parnassus Avenue, San Francisco, California, USA; daniel.cooke{at}ucsf.edu

Abstract

Retinoblastoma is a rare and curable malignancy affecting the pediatric population. For advanced stage intraocular retinoblastoma, enucleation remains the primary treatment modality, although the use of laser photocoagulation, cryotherapy, radiotherapy and chemotherapy are frequently used, particularly in the setting of bilateral disease. Intravenous chemotherapy is the long-standing method of delivery, but local administration (subtenon, intravitreal or intra-arterial) is gaining in popularity because of the reduced side effects related to systemic administration. Of these newer methods, intra-arterial infusion has demonstrated technical feasibility, few procedural complications and robust tumor response. A case is described where a collateral supply to the affected ophthalmic artery was via the zygomatico-orbital branch of the ipsilateral superficial temporal artery. Melphalan infusion was performed via this pathway without incident.

  • Aneurysm
  • angiography
  • angioplasty
  • arteriovenous malformation
  • balloon

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.